SecBot SecBot
S-1/A ·Filed Aug 19, 2026

NIMU

NON INVASIVE MONITORING SYSTEMS INC /FL/
MIXED
Impact 7/10
Horizonweeks Processed2mo ago SEC0001493152-26-039323
IPO registration amendment
Actionable Insight ◆ Mixed

Monitor the merger closing conditions, particularly Nasdaq listing approval and stockholder votes. Post-close, focus on Gravitics' ability to convert its $187M backlog into revenue, especially the Axiom CDR milestone, and its cash burn rate given the going-concern warning. The $121.7M net IPO proceeds provide a multi-year runway but the pre-revenue, high-burn profile means execution risk is extreme.

DirectionMixed
Confidencemedium
Horizonweeks
Latest settled — T+20d
NIMU ▲ +14.90% at T+20d
NEUTRAL call +14.90% · α vs SPY +14.90% · entry $10.00 → $11.49
Next anchor: T+60d in 17d
Latest observation: T+45 +14.10% FF3 residual α
Entry = T+0 close
Aug 19, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.41%
$10.00
settled 2mo ago
T+5d
0.00%
call 0.00% · α -1.11%
$10.00
settled 2mo ago
T+20d
+14.90%
call +14.90% · α +14.90%
$11.49
settled 6w ago
T+60d
Pending
in 17d

Executive Summary

Non-Invasive Monitoring Systems (NIMU), a shell company, is filing an amended S-1 to register a $125M IPO of 8,064,516 shares at an estimated $14-$17 range, concurrent with its reverse merger into space-infrastructure company Gravitics. Post-merger, Gravitics stockholders will own ~96.5% of the combined entity, which will uplist to Nasdaq under 'GVTX'. Gravitics has $187M in contracted backlog (including a $125M Axiom Space contract and a $30M US Space Force STRATFI contract) but is pre-revenue in H1 2026, deeply unprofitable ($24.5M net loss in H1 2026), and has a going-concern qualification from its auditor. The offering is contingent on merger close and Nasdaq listing; proceeds will fund R&D, manufacturing expansion, and debt repayment.

Key Financial Metrics

Price Range
$14.00-$17.00 per share

Key Facts

  • IPO of 8,064,516 shares at $14-$17 midpoint $15.50, raising ~$121.7M net ($139.2M with overallotment).
  • Reverse merger: Gravitics (space structures) merges into NIMU shell; Gravitics holders get ~96.5% of combined entity.
  • Combined company to list on Nasdaq as 'GVTX'; offering contingent on merger close and Nasdaq acceptance.
  • Gravitics has $187M in contracted backlog: $125M Axiom cargo vehicle contract (CDR-dependent), $30M US Space Force STRATFI contract, $249.9K Lockheed Martin Golden Dome subcontract.
  • Gravitics is pre-revenue in H1 2026 ($0 revenue vs $1.0M in H1 2025), with net loss of $24.5M in H1 2026 and accumulated deficit of $67.0M.
  • Gravitics auditor has going-concern qualification; cash was $2.7M as of June 30, 2026.
  • Material weakness in internal controls over financial reporting identified.
  • Pro forma combined net loss of $12.4M for H1 2026 and $36.4M for FY2025.
  • Existing NIMU shareholders diluted to ~3.5% post-merger; new IPO investors will own ~21.1% of combined company.
  • Use of proceeds: $50M manufacturing expansion, $20M R&D, $20M M&A, $15M infrastructure, $1.3M debt repayment, remainder working capital.

Financial Impact

$125M gross IPO proceeds; combined entity pro forma cash ~$117.4M; Gravitics H1 2026 net loss $24.5M; pro forma combined net loss $12.4M for H1 2026.

revenuenetIncomecashdilutiondebt

Risk Factors

  • Merger may not close (contingent on Nasdaq listing, stockholder approvals).
  • Gravitics has no current revenue, deep losses ($24.5M in H1 2026), and a going-concern qualification.
  • Material weakness in internal controls; limited public company experience of Gravitics management.
  • Heavily dependent on single large customer contracts (Axiom, US Space Force) that are terminable for convenience.
  • Spacecraft development and orbital demonstration carry high technical and schedule risk; early mission failures are common.
  • Massive dilution to existing NIMU shareholders (from 100% to ~3.5% post-merger).
  • New IPO investors face immediate dilution of $12.65 per share (82% of offering price).

Market Snapshot

Exchange
OTC
Sector
Electromedical & Electrotherapeutic Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
S-1/A Filing (Primary)0001493152-26-039323
Exhibit: ex10-9.htm0001493152-26-039323
Exhibit: ex10-12.htm0001493152-26-039323
18 reports for NIMU
Performance horizon
0% Hit rate @ T+5 0 of 3 directional calls Went positive at some point 0 of 3 best @ T+1· 0.00%Aug 17, 2026
Filters
Rows
Reports for NIMU — sortable, filterable
TypeNow
Oct 19, 2026
6d ago
S-1/A
MIXED ★ 7/10
$10.81awaiting T+5—$10.81 (+0.00%)
Oct 19, 2026
6d ago
S-4/A
NEUTRAL ★ 5/10
$10.81awaiting T+5—$10.81 (+0.00%)
Oct 19, 2026
7d ago
8-K
NEUTRAL ★ 5/10
$10.81awaiting T+5—$10.81 (+0.00%)
Oct 9, 2026
16d ago
S-1/A
MIXED ★ 7/10
$10.81 $10.81· 0.00%▲ +1.49%$10.81 (+0.00%)
Oct 9, 2026
16d ago
S-4/A
NEUTRAL ★ 6/10
$10.81 $10.81· 0.00%▲ +1.49%$10.81 (+0.00%)
Oct 6, 2026
20d ago
S-1/A
MIXED ★ 7/10
$11.50 $10.81▼ −6.00%▼ −5.86%$10.81 (−6.00%)
Oct 5, 2026
20d ago
S-4/A
BULLISH ★ 7/10
$11.50 $10.81▼ −6.00%▼ −5.86%$10.81 (−6.00%)
Oct 5, 2026
20d ago
8-K
MIXED ★ 6/10
$11.50 $10.81▼ −6.00%▼ −5.86%$10.81 (−6.00%)
Oct 2, 2026
23d ago
8-K
MIXED ★ 6/10
$11.50 $10.81▼ −6.00%▼ −6.42%$10.81 (−6.00%)
Sep 24, 2026
4w ago
S-4/A
NEUTRAL ★ 6/10
$11.50 $11.50· 0.00%▲ +0.22%$10.81 (−6.00%)
Showing 10 of 18

US Market Status

Market Open — Closes in 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 20, 2026